Skip to content
Choose language:

ABBOTT LAUNCHES MOLECULAR POINT-OF-CARE TEST TO DETECT NOVEL CORONAVIRUS IN AS LITTLE AS FIVE MINUTES

Testing being performed on Abbott’s ID NOW platform
– The Abbott
ID NOW™ COVID-19 test brings rapid testing to the front lines
– Test to run on Abbott’s point-of-care ID NOW platform – a portable instrument that can be deployed where testing is needed most
– ID NOW has the largest molecular point-of-care installed base in the U.S. and is available in a wide range of healthcare settings
– Abbott will be making ID NOW COVID-19 tests available next week and expects to ramp up manufacturing to deliver 50,000 tests per day
– This is the company’s second test to receive Emergency Use Authorization by the FDA for COVID-19 detection; combined, Abbott expects to produce about 5 million tests per month
ID NOW test components being made in Abbott’s U.S. manufacturing facility